Mylan Takes $76M Antitrust Verdict To High Court

Law360, Washington (June 27, 2011, 8:45 PM EDT) -- Mylan Laboratories Inc. asked the U.S. Supreme Court in mid-June to review a $76 million antitrust verdict brought against it over licensing agreements for two anti-anxiety medications, claiming the plaintiffs, four health insurance companies, cannot show diversity of citizenship to establish subject matter jurisdiction.

The suit, whose plaintiffs included Blue Cross & Blue Shield of Massachusetts Inc., accused generic-drug manufacturer Mylan and two chemical companies of violating state antitrust laws.

The insurance companies alleged that Mylan had entered into exclusive licensing agreements with Gyma Laboratories of...
To view the full article, register now.